Growth Metrics

Edwards Lifesciences (EW) Long-Term Deferred Tax (2016 - 2026)

Edwards Lifesciences has reported Long-Term Deferred Tax over the past 17 years, most recently at $1.1 billion for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 14.72% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 14.72%, while the annual FY2025 figure was $1.1 billion, 14.72% up from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $1.1 billion at Edwards Lifesciences, up from $1.1 billion in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $1.1 billion in Q4 2025 and troughed at $184.0 million in Q3 2021.
  • A 5-year average of $632.9 million and a median of $631.3 million in 2023 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: decreased 14.5% in 2021 and later surged 98.54% in 2023.
  • Year by year, Long-Term Deferred Tax stood at $246.7 million in 2021, then surged by 96.19% to $484.0 million in 2022, then soared by 54.83% to $749.4 million in 2023, then surged by 32.39% to $992.1 million in 2024, then increased by 14.72% to $1.1 billion in 2025.
  • Business Quant data shows Long-Term Deferred Tax for EW at $1.1 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.1 billion in Q2 2025.